Wedbush downgraded Keros Therapeutics (KROS) to Neutral from Outperform with a $15 price target after removing pulmonary arterial hypertension and obesity programs from the firm’s model.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics price target lowered to $15 from $40 at Piper Sandler
- Keros Therapeutics price target lowered to $41 from $44 at Scotiabank
- Keros Therapeutics price target lowered to $23 from $63 at Oppenheimer
- Keros Therapeutics price target lowered to $32 from $33 at BofA
- Big banks report Q4 beats, QXO proposes to buy Beacon: Morning Buzz